Neovacs SA – Product Pipeline Review – 2015
Global Markets Direct’s, ‘Neovacs SA – Product Pipeline Review – 2015’, provides an overview of the Neovacs SA’s pharmaceutical research and development focus. This report provides comprehensive information on the current therapeutic developmental pipeline of Neovacs SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target….
Total Pages: 29
Global Markets Direct’s, ‘Neovacs SA - Product Pipeline Review - 2015’, provides an overview of the Neovacs SA’s pharmaceutical research and development focus.
This report provides comprehensive information on the current therapeutic developmental pipeline of Neovacs SA’s, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.
Scope
- The report provides brief overview of Neovacs SA including business description, key information and facts, and its locations and subsidiaries
- The report reviews current pipeline of Neovacs SA’s human therapeutic division and enlists all their major and minor projects
- The report features product description and descriptive mechanism of action for key pipeline products along with the product’s developmental history and major milestones
- Special feature on out-licensed and partnered product portfolio
- The report summarizes all the dormant and discontinued pipeline projects
- Latest company statement
- Latest news and deals relating to the Neovacs SA’s pipeline products
Reasons to buy
- Evaluate Neovacs SA’s strategic position with total access to detailed information on its product pipeline
- Assess the growth potential of Neovacs SA in its therapy areas of focus
- Identify new drug targets and therapeutic classes in the Neovacs SA’s R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
- Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
- Develop strategic initiatives by understanding the focus areas of Neovacs SA and exploit collaboration and partnership opportunities
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Plan mergers and acquisitions effectively by identifying the most promising pipeline of Neovacs SA
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Explore the dormant and discontinued projects of Neovacs SA and identify potential opportunities in those areas
- Avoid Intellectual Property Rights related issues
Table of Contents
Table of Contents 2
List of Tables 4
List of Figures 4
Neovacs SA Snapshot 5
Neovacs SA Overview 5
Key Information 5
Key Facts 5
Neovacs SA - Research and Development Overview 6
Key Therapeutic Areas 6
Neovacs SA - Pipeline Review 8
Pipeline Products by Stage of Development 8
Pipeline Products - Monotherapy 9
Neovacs SA - Pipeline Products Glance 10
Neovacs SA - Clinical Stage Pipeline Products 10
Phase II Products/Combination Treatment Modalities 10
Neovacs SA - Early Stage Pipeline Products 11
Preclinical Products/Combination Treatment Modalities 11
Neovacs SA - Drug Profiles 12
Vaccine to Target Interferon Alpha for Systemic Lupus Erythematosus, Chronic Viral Infections and Dermatomyositis 12
Product Description 12
Mechanism of Action 12
R&D Progress 12
Vaccine to Target TNF Alpha for Crohn's Disease, Rheumatoid Arthritis and Psoriasis 15
Product Description 15
Mechanism of Action 15
R&D Progress 15
Vaccine to Target Interleukin 4 and Interleukin 13 for Allergies 17
Product Description 17
Mechanism of Action 17
R&D Progress 17
Vaccine to Target VEGF-Alpha for Age Related Macular Degeneration and Solid Tumors 18
Product Description 18
Mechanism of Action 18
R&D Progress 18
Neovacs SA - Pipeline Analysis 19
Neovacs SA - Pipeline Products by Target 19
Neovacs SA - Pipeline Products by Route of Administration 20
Neovacs SA - Pipeline Products by Molecule Type 21
Neovacs SA - Recent Pipeline Updates 22
Neovacs SA - Dormant Projects 26
Neovacs SA - Locations And Subsidiaries 27
Head Office 27
Other Locations & Subsidiaries 27
Appendix 28
Methodology 28
Coverage 28
Secondary Research 28
Primary Research 28
Expert Panel Validation 28
Contact Us 28
Disclaimer 29
List of Tables
Neovacs SA, Key Information 5
Neovacs SA, Key Facts 5
Neovacs SA - Pipeline by Indication, 2015 7
Neovacs SA - Pipeline by Stage of Development, 2015 8
Neovacs SA - Monotherapy Products in Pipeline, 2015 9
Neovacs SA - Phase II, 2015 10
Neovacs SA - Preclinical, 2015 11
Neovacs SA - Pipeline by Target, 2015 19
Neovacs SA - Pipeline by Route of Administration, 2015 20
Neovacs SA - Pipeline by Molecule Type, 2015 21
Neovacs SA - Recent Pipeline Updates, 2015 22
Neovacs SA - Dormant Developmental Projects,2015 26
Neovacs SA, Subsidiaries 27
